ReviewSeminars in neurology2017
Motor Complications of Dopaminergic Medications in Parkinson's Disease.
Review in Seminars in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of IPX203 in Parkinson's patients: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Continuous home monitoring of Parkinson's disease using inertial sensors: A systematic review.PloS one · 2021Pooled it
- Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.Annals of medicine · 2026Observational
- Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson's Disease: Evidence Review and Expert Opinion.PharmacoEconomics · 2026Article
- Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: An 18-Month Longitudinal Study.Journal of clinical medicine · 2026Article
- Risk-Benefit Considerations in Deep Brain Stimulation Discontinuation for Late-Stage Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Flexible and Self-Powered Wearable Sensors for Tremor Monitoring in Parkinson'S Disease: Recent Advances in Materials and Device Architectures.Advanced healthcare materials · 2026Review
- The Influence of Motor and Nonmotor Factors on Ambulatory Activity in People With Parkinson Disease.Journal of neurologic physical therapy : JNPT · 2026Article
- Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation.Inflammopharmacology · 2026Article
- Levodopa-entacapone-carbidopa intestinal gel in advanced Parkinson's disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Non-motor fluctuations in Parkinson's disease: frequency and clinical correlate.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Predictors of motor outcome with pallidal stimulation for Parkinson's disease from the CSP468 cohort.NPJ Parkinson's disease · 2026Article
- Wearable sensors for monitoring drug pharmacokinetics in patients with Parkinson's disease.Scientific reports · 2026Article
- Neuroprotective Effects of Huperzine B andAdvances in pharmacological and pharmaceutical sciences · 2026Article
- Article
- Efficacy of repetitive transcranial magnetic stimulation in Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2025Article
- Vital nutrition: enhancing health in advanced Parkinson's disease with device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson's disease: results from a real-world study.Journal of comparative effectiveness research · 2025Article
- Article
- Three-dimensional midbrain organoids: a next-generation tool for Parkinson's disease modelling and drug discovery.Stem cell research & therapy · 2025Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Motor complications are a consequence of the chronic treatment of Parkinson's disease (PD) and include motor fluctuations (wearing-off phenomenon) and levodopa-induced dyskinesia. Both can have a significant impact on functionality and quality of life; thus, proper recognition and management is essential. The phenomenology and temporal relationship of motor complications to the schedule of levodopa dosing can be helpful in characterizing them. There are several therapeutic approaches to motor complications, including pharmacological and surgical options. The authors summarize the different types of motor complications according to phenomenology and the currently available medical treatments, including ongoing trials for the management of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.